Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Infectious Disease
Non-Tubercular Mycobacteria
Questions discussed in this category
Is there a role for dual antibiotic treatment with ethambutol and macrolide only, as opposed to three-drug antibiotic therapy, in the treatment of treatment-naive pulmonary MAC without cavitary disease?
3 Answers available
What is your preferred third antimicrobial agent for a patient with treatment-naive pulmonary MAC without cavitary disease and strict contraindications to utilization of rifampin or rifabutin?
3 Answers available
Do you favor timely bronchoscopy for diagnostics over close surveillance in mildly symptomatic patients with CT findings suspicious for NTM infection who are not able to expectorate?
4 Answers available
Do add a macrolide for immunomodulatory effect in patients with macrolide-resistant M. abscessus?
2 Answers available
What are your top takeaways from ID Week 2024?
1 Answer available
What is your approach to deciding when to stop therapy for cutaneous Mycobacterium chelonae infections?
1 Answer available
What is your approach to treatment of macrolide-sensitive localized bone/joint MAC disease?
1 Answer available
In which patients do you prefer daily standard three-drug therapy for non-cavitary pulmonary MAC as opposed to three times a week dosing?
2 Answers available
Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?
1 Answer available
How long do you continue surveillance with imaging and sputum cultures in a patient with NTM with no indications for treatment?
3 Answers available
Are you using the microbial cell-free DNA “Karius” test to aid in the diagnosis of an atypical pulmonary infection such as PJP or NTM?
2 Answers available
17491
17492
18801
21109
21696
19201
17495
17493
17810
12886
12510
Papers discussed in this category
Chest, 2023 Feb 17
Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium avium Complex Pulmonary Disease.
Related Topics in Infectious Disease
Breast Cancer
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Gastrointestinal Cancers
Pediatric Hematology/Oncology
Sarcoma
Thoracic Malignancies
Bladder Cancer
Medical Oncology